Standardized low-resolution brain electromagnetic tomography (sLORETA) in the prediction of response to cholinesterase inhibitors in patients with Alzheimer's disease
- First Online:
- Cite this article as:
- Brunovsky, M., Krajca, V., Diblikova, F. et al. Ann Gen Psychiatry (2008) 7: S277. doi:10.1186/1744-859X-7-S1-S277
- 1.3k Downloads
We tried to identify subgroup of patients with Alzheimer's disease (AD) benefiting from cholinesterase inhibitors (ChEI) treatment using standardized low-resolution brain electromagnetic tomography (sLORETA) , which allows to study cortical EEG sources in 6239 cortical grey matter voxels.
Materials and methods
Resting EEG was recorded in 20 mild to moderate AD patients (mean age= 75.04 years; 13 women and 7 men; MMSE 15-24) before and after 6 months and 2 years on ChEI (donepezil, rivastigmine, galantamine) treatment. Based on changes of MMSE scores after 2 years follow-up, 11 patients were classified as Non-responders (decrease of MMSE > 2) and 9 patients as Responders (decrease of MMSE < 2). The localization of the differences in activity between two groups (at baseline) and within groups (baseline vs. 6 months) was assessed by voxel-by-voxel t-tests of the sLORETA images of the log-transformed computed current density power in seven frequency bands.
At baseline, Non-responders had significantly greater current densities in delta and alpha frequency band, which sLORETA localized in frontal (BA 6,8,9,32; alpha) and parieto-occipital (BA 7,17,39,40; delta) areas. After 6 months of ChEI treatment only Responders showed an increase of beta current densities, mainly in left frontal and temporal cortex.
Our results suggest that there is a subgroup of AD patients (probably with more pronounced central cholinergic deficiency syndrome) with better response to ChEI treatment, which can be identified by means of new quantitative EEG technique (sLORETA).
The study was supported by a grant from Ministry of Health of Czech Republic No. 1A/8600 - 4.
This article is published under license to BioMed Central Ltd.